What is Aadi Bioscience?
Aadi Bioscience is dedicated to advancing precision oncology by developing novel therapies targeting cancers driven by alterations in the mTOR pathway, specifically focusing on mutations within the TSC1 or TSC2 genes. The company aims to overcome the limitations of existing mTOR inhibitors, addressing challenges related to pharmacology, drug delivery, safety, and targeted efficacy. Aadi's strategic focus on genetically-defined cancers positions it within a rapidly evolving segment of the biopharmaceutical industry, seeking to provide much-needed options for patients with limited therapeutic alternatives.
How much funding has Aadi Bioscience raised?
Aadi Bioscience has raised a total of $195.7M across 4 funding rounds:
Series A
$23M
Debt
$150K
Share Placement
$72.5M
Share Placement
$100M
Series A (2017): $23M with participation from Celgene Corporation, Vivo Capital, Decheng Capital, Hermed Capital, and Helsinn Investment Fund
Debt (2020): $150K led by PPP
Share Placement (2022): $72.5M, investors not publicly disclosed
Share Placement (2025): $100M, investors not publicly disclosed
Key Investors in Aadi Bioscience
Celgene Corporation
Celgene Corporation is a global biopharmaceutical company known for its innovative therapies in oncology and immunology. Its investment in Aadi Bioscience suggests a strategic interest in precision medicine and novel cancer treatment modalities.
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital. Their participation indicates a belief in Aadi's long-term growth potential within the healthcare sector.
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in early-stage life science and growth-stage healthcare companies. Their involvement highlights Aadi's alignment with cutting-edge biotechnology and therapeutic innovation.
What's next for Aadi Bioscience?
With the recent infusion of capital, Aadi Bioscience is poised to advance its clinical pipeline and further its research into precision therapies. The major strategic investment signals strong confidence from backers in the company's scientific approach and market potential. Future endeavors will likely concentrate on progressing drug candidates through clinical trials, expanding its research capabilities, and potentially forging strategic partnerships to enhance its development and commercialization efforts. This funding will be critical in navigating the complex regulatory landscape and bringing its innovative treatments to patients.
See full Aadi Bioscience company page
